Immunic focusing on business development during Q4
November 14, 2023 at 01:26 pm
Share
(via NewsDirect)
Immunic Inc President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive London after the Munich-based biotech company released a third-quarter update.
Dr Vitt starts by describing the quarter as a "very eventful and positive quarter for us, dominated by a key message" - positive interim data from its Phase 2 CALLIPER trial of vidofludimus calcium in Progressive Multiple Sclerosis.
The financial aspect was also discussed, with the company claiming a cash reserve of $60 million as of the last quarter.
The interview highlights the company's efforts to bolster its intellectual property portfolio, citing a notice of allowance from the US Patent Office for the vidofludimous calcium dose strength patent.
Dr Vitt discusses the company's focus on business development during the current quarter, expressing confidence in the data and molecules its bringing to discussions with potential partners. He says that "the focus for the company is clearly on the business development side... we [also] continue execution of the vidofludimous MS programs and also prepare a potential phase 2 clinical study for IMU-856."
Contact Details
Proactive United States
+1 347-449-0879
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Companyâs s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.